NASDAQ:LNTH - Lantheus Stock Price, Price Target & More

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) announced its earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.22 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.22. The medical equipment provider earned $82.63 million during the quarter, compared to analyst estimates of $81.15 million. Lantheus had a negative return on equity of 145.14% and a net margin of 38.32%. The firm's quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company posted $0.11 earnings per share. View Lantheus' Earnings History.

4 analysts have issued twelve-month target prices for Lantheus' stock. Their predictions range from $22.00 to $27.00. On average, they anticipate Lantheus' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 71.4% from the stock's current price. View Analyst Ratings for Lantheus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Lantheus include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF) and Fluoropharma Medical (FPMI).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Media headlines about LNTH stock have trended positive on Tuesday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lantheus earned a coverage optimism score of 0.45 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 46.27 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Lantheus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.51%), Bank of Montreal Can (0.44%) and Fisher Asset Management LLC (0.26%). Company insiders that own Lantheus stock include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Fisher Asset Management LLC. Company insiders that have sold Lantheus company stock in the last year include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Michael P Duffy and Timothy G Healey. View Insider Buying and Selling for Lantheus.

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $14.00.

Lantheus has a market capitalization of $537.85 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. Lantheus employs 483 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]